Mapi Pharma Ltd.
Value-added oral and depot dosage drugs
This article was originally published in Start Up
Mapi Pharma Ltd. intends to create added-value and patentable products based on combining off-patent drugs with its innovative oral and depot delivery systems, both for its in-house pipeline and for its clients. The Israeli start-up also manufactures complex, bulk, active pharmaceutical ingredients, generic and innovative intermediates, and finished dosage forms.
You may also be interested in...
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways